Digital health firm Pear goes public, raising $175 million (pharmaforum):
Pear will make its debut on the exchange today after combining with Thimble Point – a special purpose acquisition company (SPAC) – in a deal that sidestepped the conventional initial public offering (IPO) route and has propelled its valuation to around $1.6 billion … Pear specialises in prescription digital therapeutics (DTx) based on cognitive behavioural therapy (CBT) techniques that can delivered remotely to [patients via a digital device. It has three apps approved by the FDA, including reSET and reSET‑O for people living with substance and opioid use disorders, respectively, and a tool for chronic insomniacs called Somryst. [Read more…] about Pear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics